WuXi Biologics Schedules 25 August Board Meeting to Approve H1 2026 Results

Bulletin Express

Jul 24

The Board of WuXi Biologics (Cayman) Inc. will convene on 25 August 2026 in Hong Kong to review and approve the Group’s interim results for the six months ended 30 June 2026, according to a company announcement dated 24 July 2026.

The meeting will also address publication arrangements for the forthcoming interim report.

Board composition at the time of the announcement includes: • Executive Directors: Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu • Non-executive Directors: Dr. Ge Li (Chairman), Mr. Yanling Cao and Ms. Jingwen Miao • Independent Non-executive Directors: Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125667707"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125667707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125667707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125667707","market":"us","top_or_hot":-1,"title":"WuXi Biologics Schedules 25 August Board Meeting to Approve H1 2026 Results","media":"Bulletin Express","content":"<p>The Board of WuXi Biologics (Cayman) Inc. will convene on 25 August 2026 in Hong Kong to review and approve the Group’s interim results for the six months ended 30 June 2026, according to a company announcement dated 24 July 2026.</p>\n<p>The meeting will also address publication arrangements for the forthcoming interim report.</p>\n<p>Board composition at the time of the announcement includes:\n• Executive Directors: Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu  \n• Non-executive Directors: Dr. Ge Li (Chairman), Mr. Yanling Cao and Ms. Jingwen Miao  \n• Independent Non-executive Directors: Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi Biologics Schedules 25 August Board Meeting to Approve H1 2026 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi Biologics Schedules 25 August Board Meeting to Approve H1 2026 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-24 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Board of WuXi Biologics (Cayman) Inc. will convene on 25 August 2026 in Hong Kong to review and approve the Group’s interim results for the six months ended 30 June 2026, according to a company announcement dated 24 July 2026.</p>\n<p>The meeting will also address publication arrangements for the forthcoming interim report.</p>\n<p>Board composition at the time of the announcement includes:\n• Executive Directors: Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu  \n• Non-executive Directors: Dr. Ge Li (Chairman), Mr. Yanling Cao and Ms. Jingwen Miao  \n• Independent Non-executive Directors: Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1125667707","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125667707","pubTimestamp":1784882767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The Board of WuXi Biologics (Cayman) Inc. will convene on 25 August 2026 in Hong Kong to review and approve the Group’s interim results for the six months ended 30 June 2026, according to a company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"药明生物定于 8 月 25 日召开董事会会议批准 2026 年上半年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"The Board of WuXi Biologics (Cayman) Inc. will convene on 25 August 2026 in Hong Kong to review and approve the Group’s interim results for the six months ended 30 June 2026, according to a company announcement dated 24 July 2026.\nThe meeting will also address publication arrangements for the forthcoming interim report.\nBoard composition at the time of the announcement includes:\n• Executive Directors: Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu  \n• Non-executive Directors: Dr. Ge Li (Chairman), Mr. Yanling Cao and Ms. Jingwen Miao  \n• Independent Non-executive Directors: Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}